Anúncio
Anúncio

KROS

KROS logo

Keros Therapeutics, Inc. Common Stock

19.19
USD
Patrocinado
+0.61
+3.29%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

18.96

-0.23
-1.21%

Relatórios de Lucros KROS

Rácio de surpresa positiva

KROS separação 14 de 23 últimas estimativas.

61%

Próximo Relatório

Data do Próximo Relatório
24 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.81M
/
-$0.60
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-80.28%
/
+233.33%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-7.55%
/
-46.90%

Keros Therapeutics, Inc. Common Stock earnings per share and revenue

On 05 de nov. de 2025, KROS reported earnings of -0.18 USD per share (EPS) for Q3 25, beating the estimate of -1.06 USD, resulting in a 83.14% surprise. Revenue reached 14.26 milhão, compared to an expected 3.88 milhão, with a 267.96% difference. The market reacted with a +3.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analistas forecast an EPS of -0.60 USD, with revenue projected to reach 2.81 milhão USD, implying an aumentar of 233.33% EPS, and diminuir of -80.28% in Revenue from the last quarter.
FAQ
For Q3 2025, Keros Therapeutics, Inc. Common Stock reported EPS of -$0.18, beating estimates by 83.14%, and revenue of $14.26M, 267.96% above expectations.
The stock price moved up 3.32%, changed from $15.65 before the earnings release to $16.17 the day after.
The next earning report is scheduled for 24 de fev. de 2026.
Based on 12 analistas, Keros Therapeutics, Inc. Common Stock is expected to report EPS of -$0.60 and revenue of $2.81M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio